Open data in biomedicine is a gold mine that can strengthen innovation
in pharmaceutical R&D. In combination with the right analytics, public
data helps identify therapeutic targets and ligands, enhance clinical
development, and boost portfolio management efficiency. The challenge is to
purposefully integrate abundant and heterogeneous data scattered across
Data science projects are successful when they produce actionable
results over several years. Since databases constitute the foundation of
those endeavours, their selection is highly strategic, and the biomedical
field is no exception to that rule.
Biomedicine is a central driving force of the rise of big data.
High-throughput screening and the increase of computing power have led to
the generation of vast amounts of data, opening new avenues for
A new medicine is granted market approval if clinical trials can show an
acceptable risk-benefit profile compared to a control. The therapy’s
safety and its efficacy against the treated disease are assessed through
clinical endpoints, which embody the study’s targeted
Hospitals, emergency and operating rooms are crucial components of our
healthcare infrastructure. For years, medical doctors have worked in the
same environment. With the rise of technology, one of the oldest
professions on earth is now bound to change.
Big data potential and data protection are not necessarily reinforcing
each other. Especially in medtech, the vast promises of big data and data
science are significantly constrained by patient data protection